Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells

Gene Therapy

Volumn 15, Issue 4, 2008, Pages 298-308

  Huang, D ^a   Pereboev, A V ^b   Korokhov, N ^b   He, R ^c   Larocque, L ^a   Gravel, C ^a   Jaentschke, B ^a   Tocchi, M ^a   Casley, W L ^a   Lemieux, M ^a   Curiel, D T ^b   Chen, W ^d   Li, X ^a,e  

^a Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals   (Canada)

^b University of Alabama at Birmingham   (United States)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG DISTRIBUTION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD40; DENDRITIC CELLS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; TISSUE DISTRIBUTION; TRANSGENES;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MUS;

EID: 38949191964     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303085     Document Type: Article

References (54)

1. Noureddini SC, Curiel DT. Genetic targeting strategies for adenovirus. Mol Pharm 2005; 2: 341-347.
2. Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005; 18 283-291.
3. Okada N, Masunaga. Y, Okada Y, Mizuguchi H, Iiyama S, Mori N et al Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Therapy 2003; 10: 1891-1902.
4. Cicho G, Schmidt HH, Benhidjeb T, Loser P, Ziemer S, Haas R et al. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J Gene Med 1999; 1: 360-371.
5. Smith JS, Tian J, Muller J, Byrnes AP. Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Therapy 2004; 11: 431-438.
6. Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166 5236-5244.
7. Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, Merritt R et al Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 2004; 78: 2572-2580.
8. Brandao JG, Scheper RJ, Lougheed SM, Curiel DT, Tillman BW, Gerritsen WR et al. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003; 21: 2268-2272.
9. Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, Kawakami Y et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 2004; 9: 712-720.
10. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth Jr RJ. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161: 2094-2098.
11. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-celI help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483.
12. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480.
13. Shayakhmetov DM, Eberly AM, Li ZY, Lieber A. Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol 2005; 79: 1053-1061.
14. Nakamura T, Sato K, Hamada H. Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol 2003; 77: 2512-2521.
15. Tripp RA, Jones L, Anderson LJ, Brown MP. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse. J Immunol 2000; 164: 5913-5921.
16. Ninomiya A, Ogasawara K, Kajino K, Takada A, Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 2002; 20: 3123-3129.
17. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 2006; 80: 1762-1772.
18. Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol 2000; 164: 1230-1235.
19. Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM. CD40-independent pathways of T cell help for printing of CD8(+) cytotoxic T lymphocytes. J Exp Med 2001; 191: 541-550.
20. Hemminki A, Wang M, Desmond RA, Strong TY, Alvarez RD, Curiel DT. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2002; 13; 1505-1514.
21. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3: 28-35.
22. Zinn KR, Douglas JT, Smyth CA, Liu HG, Wu Q. Krasnykh VN et al. Imaging hnd tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5). Gene Therapy 1998, 5: 798-808.
23. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L et al Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999; 6: 367-372.
24. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging af Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004; 9: 436-442.
25. Rock KL, Shen L. Cross-presenntation: Underlying mechanisms and role in immune surveillance. Immunol Rev 2005; 207: 166-183.
26. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998; 102: 1112-1124.
27. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004; 199: 84-99.
28. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
29. Dubois B, Vanbervliet B, Fayette J, Massacrier C, Van Kooten C, Briere F et al. Dendritic cells enhance growth and differentiation of CD40-activated. B lymphocytes. J Exp Med 1997; 185: 941-951.
30. Clark EA. Regulation of B lymphocytes by dendritic cells. J Exp Med 1997; 185: 801-803.
31. Fayette J, Dubois B, Vandenabeele S, Bridon JM, Vanbervliet B, Durand I et al. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 1997; 185: 1909-1918.
32. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
33. Mendoza RB, Cantwell MJ, Kipps TJ. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol 1997; 159: 5777-5781.
34. Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C et al CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunnity to infectious and tumor challenge. J Immunol 1998; 161: 4563-4571.
35. Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP et al. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 2003; 171 697-707.
36. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, Mizuguchi H. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alpha V integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 2006; 17: 264-279.
37. Leissner P, Legrand V, Schlesinger Y, Hadji DA, Van Raaij M, Cusack S et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Therapy 2001; 8: 49-57.
38. Sherer Y, Corstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004; 34: 501-537.
39. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
40. Manickan E, Smith JS, Tian J, Eggerman TL, Lozier JN, Muller J et al Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mo Ther 2006; 13: 108-117.
41. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997; 16: 2294-2306.
42. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
43. Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, Chakrabarti BK et al Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003; 77: 10078-10087.
44. Franklin R, Quick M, Haase G. Adenoviral vectors for in vivo gene delivery to oligodendrocytes: Transgene expression and cytopathic consequences. Gene Therapy 1999; 6: 1360-1367.
45. He R, Leeson A, Andonov A, Li Y, Bastien N, Cao J et al. Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein. Biochem Biophys Res Commun 2003; 311: 870-876.
46. Nicholls JM, Butany J, Poon LL, Chan KH, Beh SL, Poutanen S et al. Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Med 2006; 3: E27.
47. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-779.
48. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199: 815-824.
49. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD48 induces protective immune responses against tumors. J Immunol 2007; 178 4169-4176.
50. Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P et al Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 2007; 81: 1083-1094.
51. Rothstein TL, Wang JK, Panka DJ, Foote LC, Wang Z, Stanger B et al Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374: 163-165.
52. Majlessi L, Bordenave G. Role of CD40 in a T cell-mediated negative regulation of Ig production. J Immunol 2001; 166: 841-847.
53. Erickson LD, Duren BG, Vogel LA, O'Connor BP, Cascalho M, Yasui T et al. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest 2002; 109: 613-620.
54. Schilizzi BM, Boonstra R, The TH, de Leij LF. Effect of B-cell receptor engagement on CD40-stimulated B cells. Immunology 1997; 92: 346-353.